S879 RESULTS OF ASTRAL-1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC)

Authors :: Patricia Kropf
X. Thomas
P. Fenaux
J. Brandwein
Y. H. Min
J. Krauter
J. Novak
H. Kantarjian
J. Mayer
G.J. Roboz
Mohammad Azab
Hartmut Döhner
Wiesław Wiktor Jędrzejczak
Judit Demeter
K. Döhner
Y. Miyazaki
L. Gercheva-Kyuchukova
M. Gobbi
J.-P. Issa
Elizabeth A. Griffiths
T. Robak
K. Yee
S.-P. Yeh
M. Ojeda-Uribe
Source :: HemaSphere. 3:394-395
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
Therapy naive
medicine.medical_specialty
Randomized controlled trial
business.industry
law
Internal medicine
medicine
Myeloid leukemia
Hematology
Intensive chemotherapy
business
law.invention

Full Text Access

Tools